Drug Profile
PF 6413367
Alternative Names: NIC7-003; PF-06413367; PF6413367Latest Information Update: 05 Apr 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Smoking cessation therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 05 Apr 2016 No development reported - Phase-I for Smoking withdrawal in Canada (IM)
- 01 Dec 2015 Pfizer completes a phase I trial in Smoking withdrawal in Canada (NCT01672645)
- 01 Jun 2012 Phase-I clinical trials in Smoking withdrawal in Canada (IM)